Shenzhen Hepalink Pharmaceutical Group Co Ltd banner
S

Shenzhen Hepalink Pharmaceutical Group Co Ltd
SZSE:002399

Watchlist Manager
Shenzhen Hepalink Pharmaceutical Group Co Ltd
SZSE:002399
Watchlist
Price: 12.14 CNY 0.75% Market Closed
Market Cap: ¥17.8B

Balance Sheet

Balance Sheet Decomposition
Shenzhen Hepalink Pharmaceutical Group Co Ltd

Balance Sheet
Shenzhen Hepalink Pharmaceutical Group Co Ltd

Rotate your device to view
Balance Sheet
Currency: CNY
Dec-2007 Dec-2008 Dec-2009 Dec-2010 Dec-2011 Dec-2012 Dec-2013 Dec-2014 Dec-2015 Dec-2016 Dec-2017 Dec-2018 Dec-2019 Dec-2020 Dec-2021 Dec-2022 Dec-2023 Dec-2024
Assets
Cash & Cash Equivalents
32
161
445
6 259
6 774
6 588
6 050
4 126
4 187
4 549
3 597
1 863
1 216
2 712
2 933
2 139
1 766
1 422
Cash
0
0
0
0
0
0
0
0
1
1
0
0
0
0
1 480
1 320
1 766
1 422
Cash Equivalents
32
161
445
6 259
6 774
6 588
6 050
4 126
4 186
4 548
3 597
1 863
1 216
2 712
1 453
819
0
0
Short-Term Investments
0
0
0
0
1
1
1
0
0
13
0
77
113
828
941
2 014
500
868
Total Receivables
90
108
285
515
433
545
354
477
575
729
1 122
1 377
1 752
2 026
1 938
1 927
1 529
1 516
Accounts Receivables
82
106
198
291
305
354
196
383
461
481
701
1 084
1 294
1 659
1 533
1 618
1 271
1 183
Other Receivables
8
2
87
224
128
191
158
94
114
248
421
293
458
367
405
309
257
334
Inventory
88
259
579
1 190
456
549
677
884
570
585
1 285
1 659
2 374
3 168
4 708
6 844
6 654
5 394
Other Current Assets
3
2
30
25
52
65
96
1 271
1 150
827
578
623
540
394
251
285
155
292
Total Current Assets
213
530
1 339
7 989
7 717
7 748
7 178
6 758
6 482
6 703
6 583
5 599
5 996
9 129
10 770
12 390
10 604
9 621
PP&E Net
41
40
115
105
182
325
534
895
1 103
1 223
1 881
2 439
2 576
2 571
2 537
2 477
2 634
2 648
PP&E Gross
41
40
115
105
182
325
0
895
1 103
1 223
1 881
2 439
2 576
2 571
2 537
2 477
2 634
2 648
Accumulated Depreciation
29
35
41
51
59
72
0
143
216
321
516
705
900
1 049
1 261
1 555
1 868
2 134
Intangible Assets
2
3
3
29
72
71
178
174
706
706
720
745
683
631
587
572
493
406
Goodwill
0
0
0
0
0
0
0
1 298
2 192
2 342
2 206
2 317
2 355
2 203
2 152
2 351
2 322
2 357
Note Receivable
0
0
0
0
0
0
0
0
0
0
3
8
0
3
2
1
1
0
Long-Term Investments
0
0
0
0
0
0
256
604
1 377
1 485
2 083
1 985
3 280
3 999
2 618
2 464
2 514
1 823
Other Long-Term Assets
2
6
4
5
4
117
125
202
308
454
644
509
354
491
443
561
635
488
Other Assets
0
0
0
0
0
0
0
1 298
2 192
2 342
2 206
2 317
2 355
2 203
2 152
2 351
2 322
2 357
Total Assets
258
N/A
579
+124%
1 461
+152%
8 127
+456%
7 974
-2%
8 260
+4%
8 271
+0%
9 930
+20%
12 168
+23%
12 914
+6%
14 119
+9%
13 602
-4%
15 242
+12%
19 026
+25%
19 108
+0%
20 816
+9%
19 203
-8%
17 344
-10%
Liabilities
Accounts Payable
0
10
1
18
2
53
73
98
99
71
164
205
229
239
386
427
302
300
Accrued Liabilities
2
4
3
15
23
24
24
56
74
85
122
230
184
222
203
199
191
167
Short-Term Debt
0
122
180
0
0
74
0
4
50
508
1 843
1 981
2 927
1 860
1 886
2 385
1 881
1 839
Current Portion of Long-Term Debt
0
0
0
0
0
0
0
0
607
1 318
1 572
482
1 012
648
1 414
1 671
1 782
567
Other Current Liabilities
26
55
131
59
15
22
35
29
91
84
116
1 764
615
644
903
893
831
826
Total Current Liabilities
28
192
314
92
40
171
132
186
920
2 066
3 817
4 663
4 967
3 613
4 791
5 576
4 986
3 699
Long-Term Debt
80
76
64
0
0
0
0
1 005
1 785
2 095
1 824
2 449
2 355
3 137
2 354
2 407
1 900
1 139
Deferred Income Tax
0
0
10
9
9
9
37
270
544
547
317
197
302
428
275
329
253
242
Minority Interest
0
0
5
32
98
84
82
83
74
117
200
177
124
120
112
97
75
53
Other Liabilities
3
3
2
2
10
34
34
116
126
116
129
126
147
159
164
94
76
61
Total Liabilities
111
N/A
271
+144%
396
+46%
135
-66%
158
+17%
298
+89%
285
-4%
1 661
+483%
3 449
+108%
4 942
+43%
6 288
+27%
7 612
+21%
7 895
+4%
7 457
-6%
7 697
+3%
8 503
+10%
7 290
-14%
5 195
-29%
Equity
Common Stock
90
90
360
400
800
800
800
800
800
1 247
1 247
1 247
1 247
1 467
1 467
1 467
1 467
1 467
Retained Earnings
39
201
688
1 897
1 719
1 864
1 701
1 799
2 139
2 068
1 898
2 394
3 411
4 212
4 184
4 861
3 931
4 578
Additional Paid In Capital
17
17
17
5 694
5 297
5 298
5 322
5 278
5 278
4 219
4 462
2 304
2 634
6 035
5 944
5 859
6 356
5 865
Unrealized Security Profit/Loss
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
85
94
128
Treasury Stock
0
0
0
0
0
0
0
0
116
0
0
0
0
0
0
0
0
0
Other Equity
0
0
0
0
0
0
163
392
618
437
224
45
55
145
183
210
252
366
Total Equity
146
N/A
308
+111%
1 065
+246%
7 992
+650%
7 816
-2%
7 962
+2%
7 986
+0%
8 270
+4%
8 719
+5%
7 971
-9%
7 831
-2%
5 990
-24%
7 347
+23%
11 569
+57%
11 411
-1%
12 313
+8%
11 913
-3%
12 149
+2%
Total Liabilities & Equity
258
N/A
579
+124%
1 461
+152%
8 127
+456%
7 974
-2%
8 260
+4%
8 271
+0%
9 930
+20%
12 168
+23%
12 914
+6%
14 119
+9%
13 602
-4%
15 242
+12%
19 026
+25%
19 108
+0%
20 816
+9%
19 203
-8%
17 344
-10%
Shares Outstanding
Common Shares Outstanding
288
288
1 152
1 280
1 280
1 280
1 280
1 280
1 274
1 247
1 247
1 247
1 247
1 467
1 467
1 467
1 467
1 467
Get AI-powered insights for any company or topic.
Open AI Assistant

Intrinsic Value is all-important and is the only logical way to evaluate the relative attractiveness of investments and businesses.

Warren Buffett